517.13 USD
+10.13 (+2%)
517.13 USD
0 (0%)
UTHR gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. UTHR gets an excellent profitability rating and is at the same time showing great financial health properties. UTHR has a decent growth rate and is not valued too expensively. These ratings would make UTHR suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year UTHR was profitable.
In the past year UTHR had a positive cash flow from operations.
UTHR had positive earnings in each of the past 5 years.
UTHR had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.30%, UTHR belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
UTHR has a Return On Equity of 19.30%. This is amongst the best in the industry. UTHR outperforms 95.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 17.33%, UTHR belongs to the top of the industry, outperforming 96.99% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for UTHR is below the industry average of 18.22%.
The 3 year average ROIC (14.96%) for UTHR is below the current ROIC(17.33%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROIC | 17.33% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
1.3 Margins
UTHR has a better Profit Margin (40.65%) than 96.99% of its industry peers.
UTHR's Profit Margin has improved in the last couple of years.
UTHR has a Operating Margin of 48.65%. This is amongst the best in the industry. UTHR outperforms 99.44% of its industry peers.
In the last couple of years the Operating Margin of UTHR has grown nicely.
UTHR's Gross Margin of 88.59% is amongst the best of the industry. UTHR outperforms 90.60% of its industry peers.
UTHR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% |
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so UTHR is creating value.
UTHR has less shares outstanding than it did 1 year ago.
UTHR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for UTHR has been reduced compared to a year ago.
2.2 Solvency
UTHR has an Altman-Z score of 20.71. This indicates that UTHR is financially healthy and has little risk of bankruptcy at the moment.
UTHR has a better Altman-Z score (20.71) than 89.29% of its industry peers.
UTHR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 20.71 |
ROIC/WACC1.98
WACC8.74%
2.3 Liquidity
A Current Ratio of 6.40 indicates that UTHR has no problem at all paying its short term obligations.
UTHR has a Current ratio of 6.40. This is in the better half of the industry: UTHR outperforms 65.23% of its industry peers.
A Quick Ratio of 6.07 indicates that UTHR has no problem at all paying its short term obligations.
UTHR has a Quick ratio of 6.07. This is in the better half of the industry: UTHR outperforms 64.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.90% over the past year.
UTHR shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.88% yearly.
UTHR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.50%.
Measured over the past years, UTHR shows a quite strong growth in Revenue. The Revenue has been growing by 14.71% on average per year.
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
3.2 Future
The Earnings Per Share is expected to grow by 11.57% on average over the next years. This is quite good.
Based on estimates for the next years, UTHR will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
UTHR is valuated rather expensively with a Price/Earnings ratio of 19.60.
Compared to the rest of the industry, the Price/Earnings ratio of UTHR indicates a rather cheap valuation: UTHR is cheaper than 94.55% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.39, UTHR is valued a bit cheaper.
With a Price/Forward Earnings ratio of 17.38, UTHR is valued on the expensive side.
Based on the Price/Forward Earnings ratio, UTHR is valued cheaply inside the industry as 95.30% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of UTHR to the average of the S&P500 Index (23.84), we can say UTHR is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.6 | ||
| Fwd PE | 17.38 |
4.2 Price Multiples
96.43% of the companies in the same industry are more expensive than UTHR, based on the Enterprise Value to EBITDA ratio.
UTHR's Price/Free Cash Flow ratio is rather cheap when compared to the industry. UTHR is cheaper than 95.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 19.95 | ||
| EV/EBITDA | 11.26 |
4.3 Compensation for Growth
UTHR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of UTHR may justify a higher PE ratio.
PEG (NY)1.6
PEG (5Y)1.16
EPS Next 2Y9.98%
EPS Next 3Y8.48%
5. Dividend
5.1 Amount
No dividends for UTHR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
517.13
+10.13 (+2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.66%
Inst Owner Change-5.19%
Ins Owners1.84%
Ins Owner Change3.47%
Market Cap22.27B
Revenue(TTM)3.13B
Net Income(TTM)1.27B
Analysts80.95
Price Target520.16 (0.59%)
Short Float %4.2%
Short Ratio3.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.9%
Min EPS beat(2)-9.46%
Max EPS beat(2)-2.35%
EPS beat(4)0
Avg EPS beat(4)-4.02%
Min EPS beat(4)-9.46%
Max EPS beat(4)-0.45%
EPS beat(8)2
Avg EPS beat(8)-2.47%
EPS beat(12)5
Avg EPS beat(12)-3.15%
EPS beat(16)7
Avg EPS beat(16)-2.98%
Revenue beat(2)0
Avg Revenue beat(2)-3.23%
Min Revenue beat(2)-3.81%
Max Revenue beat(2)-2.65%
Revenue beat(4)1
Avg Revenue beat(4)-0.39%
Min Revenue beat(4)-3.81%
Max Revenue beat(4)6.71%
Revenue beat(8)5
Avg Revenue beat(8)1.56%
Revenue beat(12)7
Avg Revenue beat(12)1.27%
Revenue beat(16)9
Avg Revenue beat(16)1.26%
PT rev (1m)4.11%
PT rev (3m)10.02%
EPS NQ rev (1m)-1.38%
EPS NQ rev (3m)1.69%
EPS NY rev (1m)-1.69%
EPS NY rev (3m)-0.35%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.62%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.6 | ||
| Fwd PE | 17.38 | ||
| P/S | 7.12 | ||
| P/FCF | 19.95 | ||
| P/OCF | 14.31 | ||
| P/B | 3.38 | ||
| P/tB | 3.44 | ||
| EV/EBITDA | 11.26 |
EPS(TTM)26.39
EY5.1%
EPS(NY)29.75
Fwd EY5.75%
FCF(TTM)25.93
FCFY5.01%
OCF(TTM)36.14
OCFY6.99%
SpS72.65
BVpS153.05
TBVpS150.34
PEG (NY)1.6
PEG (5Y)1.16
Graham Number301.46
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.3% | ||
| ROE | 19.3% | ||
| ROCE | 22.37% | ||
| ROIC | 17.33% | ||
| ROICexc | 29.21% | ||
| ROICexgc | 30.07% | ||
| OM | 48.65% | ||
| PM (TTM) | 40.65% | ||
| GM | 88.59% | ||
| FCFM | 35.69% |
ROA(3y)14%
ROA(5y)12.47%
ROE(3y)16.72%
ROE(5y)15.47%
ROIC(3y)14.96%
ROIC(5y)13.31%
ROICexc(3y)29.18%
ROICexc(5y)24.89%
ROICexgc(3y)30.03%
ROICexgc(5y)25.71%
ROCE(3y)19.31%
ROCE(5y)17.18%
ROICexgc growth 3Y23.22%
ROICexgc growth 5Y4.92%
ROICexc growth 3Y22.46%
ROICexc growth 5Y5.97%
OM growth 3Y7.2%
OM growth 5Y2.85%
PM growth 3Y13.74%
PM growth 5YN/A
GM growth 3Y-1.27%
GM growth 5Y-0.58%
F-Score8
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 533.09% | ||
| Cap/Sales | 14.06% | ||
| Interest Coverage | 81.39 | ||
| Cash Conversion | 96.99% | ||
| Profit Quality | 87.79% | ||
| Current Ratio | 6.4 | ||
| Quick Ratio | 6.07 | ||
| Altman-Z | 20.71 |
F-Score8
WACC8.74%
ROIC/WACC1.98
Cap/Depr(3y)347.88%
Cap/Depr(5y)280.91%
Cap/Sales(3y)8.54%
Cap/Sales(5y)7.36%
Profit Quality(3y)85.86%
Profit Quality(5y)98.64%
High Growth Momentum
Growth
EPS 1Y (TTM)15.9%
EPS 3Y34.86%
EPS 5Y16.88%
EPS Q2Q%12.05%
EPS Next Y12.23%
EPS Next 2Y9.98%
EPS Next 3Y8.48%
EPS Next 5Y11.57%
Revenue 1Y (TTM)13.5%
Revenue growth 3Y19.52%
Revenue growth 5Y14.71%
Sales Q2Q%6.76%
Revenue Next Year11.53%
Revenue Next 2Y8.62%
Revenue Next 3Y8.84%
Revenue Next 5Y11.21%
EBIT growth 1Y12.9%
EBIT growth 3Y28.12%
EBIT growth 5Y17.97%
EBIT Next Year20.27%
EBIT Next 3Y4.67%
EBIT Next 5Y-4.6%
FCF growth 1Y46.07%
FCF growth 3Y31.3%
FCF growth 5YN/A
OCF growth 1Y62.87%
OCF growth 3Y30.42%
OCF growth 5YN/A
UNITED THERAPEUTICS CORP / UTHR FAQ
What is the fundamental rating for UTHR stock?
ChartMill assigns a fundamental rating of 7 / 10 to UTHR.
Can you provide the valuation status for UNITED THERAPEUTICS CORP?
ChartMill assigns a valuation rating of 6 / 10 to UNITED THERAPEUTICS CORP (UTHR). This can be considered as Fairly Valued.
What is the profitability of UTHR stock?
UNITED THERAPEUTICS CORP (UTHR) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for UTHR stock?
The Price/Earnings (PE) ratio for UNITED THERAPEUTICS CORP (UTHR) is 19.6 and the Price/Book (PB) ratio is 3.38.
What is the financial health of UNITED THERAPEUTICS CORP (UTHR) stock?
The financial health rating of UNITED THERAPEUTICS CORP (UTHR) is 9 / 10.